OXFORD BIODYNAMICS ORD GBP0.001 overview

Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD’s technology in a multi-centre study using blood to detect colorectal cancer (CRC), including early stage, and non-cancerous polyps with high accuracy 1 . The peer-reviewed work, published in the high-impact journal 'Cancers', was a collaboration between OBD, Norwich Medical...

Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests based on the EpiSwitch® 3D genomics platform, announces the publication of compelling results involving OBD’s technology in the multi-disciplinary PROSTAGRAM study using blood to detect prostate cancer in an at risk population. These results were referred to in the recent results statement . The peer-reviewed work, published in the high-impact journal, Cancers , was a collaboration...

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch ® 3D genomics platform, announced that its senior leadership will be in San Francisco during the 41 st Annual J.P. Morgan Healthcare Conference, Jan 9-12 2023. OBD concluded a successful year in 2022, with its flagship EpiSwitch Checkpoint Inhibitor Response Test (CiRT) made available and in commercial use both in the UK and the US, where it also...

Oxford BioDynamics, Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, announces the initial results from an interim analysis conducted for the REFINE-ALS prospective trial. The results from a subset of data, highlight the blood-based EpiSwitch prognostic stratification of patients with fast progressing Amyotrophic Lateral Sclerosis (ALS). The Phase 4 REFINE-ALS trial ( NCT04259255 ) [1] is a...

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing precision medicine tests for immune health based on the EpiSwitch® 3D genomics platform, has announced that its flagship Checkpoint inhibitor Response Test (CiRT) clinical blood test is now available to private physicians considering ICI therapy for their patients in the UK. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220620005553/en/ EpiSwitch®...

Oxford BioDynamics Plc (AIM: OBD, the Company), a biotechnology company developing targeted clinical diagnostic tests for immune health utilizing its EpiSwitch ® 3D genomics technology, announces that it has been awarded an FNIH Partnership for Accelerating Cancer Therapies (PACT) Grant to use the EpiSwitch diagnostic platform for accurate prediction of a patient’s response to Immune Checkpoint Inhibitors (ICIs) from a routine blood sample. The grant worth $910,000 (RFA #2021-PACT001) is...

Oxford BioDynamics' EpiSwitch™ Featured in Presentations on Development and Validation of Blood-Based Predictive Biomarkers in Immune Checkpoint Inhibitor Programs - Data from study of EpiSwitch™ suggest independent predictive power of the 3D genome architecture technology platform in immuno-oncology - Posters presented at Society for Immunotherapy of Cancer (SITC) Annual Meeting co-authored by scientists from Merck KGaA, Darmstadt, Germany, Pfizer and Mayo Clinic PR Newswire OXFORD, United...

Oxford BioDynamics Joins ALS Biomarker Study Sponsored By Mitsubishi Tanabe Pharma America Proprietary Technology Platform to Assess Biomarker Panels in People with ALS PR Newswire JERSEY CITY, N.J., May 3, 2019 JERSEY CITY, N.J. , May 3, 2019 /PRNewswire/ -- Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced Oxford BioDynamics has joined the REFINE-ALS study , which was designed to identify and measure specific biomarkers in people with amyotrophic lateral sclerosis (ALS). Using an...